MedTrace Logo

Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine

NCT01548326 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2012-03-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether short-term Atorvastatin can increase the immunity response to hepatitis B vaccination in vaccine Nonresponders.

Conditions

Interventions

DRUG

Atorvastatin

one 40 mg Atorvastatin tablet orally per day for 10 days

DRUG

placebo

one Placebo tablet orally per day for 10 days

Sponsors & Collaborators

  • Nematollah Jonaidi Jafari

    lead OTHER

Principal Investigators

  • Nematollah Jonaidi Jafari, MD · Baqiyatallah University of Medical Sciencesc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01548326 on ClinicalTrials.gov